MTTI Wins $3.17M NCI Grant for Lung Cancer Therapy

Molecular Targeting Technologies has a five-year federal assignment: turn a promising radiopharmaceutical experiment into a development program sturdy enough for regulators, manufacturers, clinicians, and eventually patients. The West Chester, Pennsylvania company announced a $3.17M National Cancer Institute grant for 177Lu-EBRGD, an investigational therapy for non-small cell lung cancer.

The amount needs careful accounting. MTTI describes the award as a $3.17M, five-year program, while the official NIH record currently lists $637,529 for the first budget period ending July 31, 2027. The project runs through July 31, 2031, and its stated work spans additional animal studies, cGMP drug-product manufacturing, regulatory preparation, and planning for a clinical study.

What the NCI Grant Funds

The grant, 1R01CA299133-01, names MTTI Chairman and CEO Koon Yan "Chris" Pak, Ph.D., as the contact principal investigator. NIH describes the program as targeted radionuclide therapy for NSCLC using 177Lu-EBRGD, with specific aims covering preclinical validation, manufacturing, an Investigational New Drug submission, and eventual evaluation in adults with metastatic disease after first-line systemic therapy.

That sequence is the real financing story. A molecule can produce compelling mouse data and still be separated from a patient by pharmacology, dosimetry, toxicology, manufacturing controls, regulatory documentation, clinical operations, and a long list of questions that do not care how elegant the original experiment looked. NCI is funding MTTI to build that bridge in order rather than treating a positive model as a finished therapy.

This is also a research grant, not an equity round. There is no disclosed valuation, investor syndicate, ownership stake, or venture round attached to the award. The company-announced $3.17M represents the five-year program value, while the NIH database provides the currently recorded first-year award, and those figures should not be collapsed into a fictional capital total.

How 177Lu-EBRGD Is Designed to Work

177Lu-EBRGD combines 3 functional pieces. The RGD peptide is designed to target integrin αvβ3, a receptor associated with tumor cells and the blood vessels that support tumor growth. Lutetium-177 supplies the radioactive payload, and an Evans Blue-derived component binds reversibly to albumin in an effort to extend circulation and change where the molecule accumulates.

That last element is part of MTTI's EvaThera platform. The operating theory is straightforward even when the chemistry is not: a targeted radiopharmaceutical cannot deliver useful radiation if it clears too quickly or spends too little time in the tumor. Albumin binding is intended to extend the opportunity for the molecule to reach its target, remain there, and increase tumor exposure without simply increasing administered radioactivity.

A peer-reviewed preclinical study provides the scientific rationale for the new work. In NSCLC patient-derived xenograft models, 177Lu-EBRGD showed higher tumor accumulation and longer retention than the non-albumin-binding 177Lu-RGD comparator. A single 18.5 MBq dose eradicated high-integrin-expression tumors during the observation period, while a 29.6 MBq dose delayed growth in low-expression models.

Those results are meaningful animal evidence and nothing more. They do not establish safety, efficacy, dose, durability, or clinical benefit in people. The different responses across the 2 models also make patient selection, tumor biology, dosimetry, and normal-tissue exposure central development questions rather than details to solve later.

Why Translation Is the Hard Part

MTTI's announcement divides the program into preclinical evaluation, cGMP manufacturing, regulatory preparation, and clinical development planning. Each workstream can invalidate the assumptions made by the one before it. A therapy has to be reproducible as a drug product, supported by an evidence package regulators can assess, and operationally ready for a trial that protects patients while answering the scientific question.

MTTI is entering that process with a broader radiopharmaceutical platform rather than a single isolated construct. The company identifies 177Lu-EBTATE, which targets somatostatin receptor 2 in gastroenteropancreatic neuroendocrine tumors, as its lead clinical program. It also lists planned EB-FAPI and EB-GRPR projects, although those pipeline plans and their timing remain company-reported.

Pak brings direct responsibility for the new grant as both CEO and principal investigator. MTTI's current leadership page also names Norman LaFrance, M.D., as Chief Strategy Officer, Jeffrey A. Mattis, Ph.D., as SVP of Scientific & Regulatory Affairs, and Brian D. Gray, Ph.D., as SVP of Research. The grant now gives that team a defined federal program against which progress can be measured.

What This Signals for Radiopharmaceutical Development

Radiopharmaceutical programs are often discussed through target biology and isotope supply, but translation depends on a less glamorous stack. Chemistry, pharmacokinetics, manufacturing, dosimetry, regulatory strategy, imaging, patient selection, and clinical operations have to meet inside the same product. A weak handoff between any 2 of those layers can strand good biology before it becomes useful medicine.

NSCLC provides a demanding test. The National Cancer Institute continues to describe advanced lung cancer as a major unmet need, and the proposed MTTI study population would include patients with metastatic disease after first-line systemic therapy. That clinical setting raises the standard for evidence because patients need a credible therapeutic window, not another promising mechanism.

The next milestones are therefore concrete. MTTI must reproduce and extend the preclinical package, establish cGMP manufacturing, characterize distribution and safety, prepare an IND, and design a clinical study capable of separating biological promise from patient benefit. The grant pays for those questions to become answerable, and the future of 177Lu-EBRGD will be decided by the quality of the answers rather than the size of the announcement.